<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    No articles found.

    Relmada Therapeutics, Inc.

    Relmada Therapeutics, Inc.

    We are a clinical stage, publicly traded specialty pharmaceutical company, focused...

    We are a clinical stage, publicly traded specia...

    AMAG Pharmaceuticals, Inc.

    AMAG Pharmaceuticals, Inc.

    Headquartered in Waltham, Massachusetts, we develop and deliver innovative medicin...

    Headquartered in Waltham, Massachusetts, we dev...

    Surface Oncology, Inc.

    Surface Oncology, Inc.

    Surface Oncology is an immuno-oncology company on a mission to break through and d...

    Surface Oncology is an immuno-oncology company ...

    Oncternal Therapeutics, Inc.

    Oncternal Therapeutics, Inc.

    Oncternal Therapeutics is a clinical-stage oncology company developing a diverse p...

    Oncternal Therapeutics is a clinical-stage onco...

    Catalyst Pharmaceuticals, Inc.

    Catalyst Pharmaceuticals, Inc.

    Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and ...

    Catalyst Pharmaceuticals is a biopharmaceutical...

    Supernus Pharmaceuticals, Inc.

    Supernus Pharmaceuticals, Inc.

    Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing a...

    Supernus Pharmaceuticals, Inc. is a pharmaceuti...

    Alexion Pharmaceuticals, Inc.

    Alexion Pharmaceuticals, Inc.

    Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving pa...

    Alexion (NASDAQ: ALXN) is a global biopharmaceu...

    BioCryst Pharmaceuticals, Inc.

    BioCryst Pharmaceuticals, Inc.

    BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat...

    BioCryst Pharmaceuticals discovers novel, oral ...

    BioMarin Pharmaceutical Inc.

    BioMarin Pharmaceutical Inc.

    At BioMarin, we focus on developing first-in-class and best-in-class therapeutics ...

    At BioMarin, we focus on developing first-in-cl...